|

WAL0921 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • Walden Biosciences1

Indications

  • Primary Membranous Nephropathy1
  • Primary Immunoglobulin A Nephropathy1
  • Minimal Change Disease1
  • Primary Focal Segmental Glomerulosclerosis1
  • Diabetic Nephropathies1

Los Angeles, California1 trial

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Academic Medical Research Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.